Cargando…

Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer

RATIONALE: Recent studies have discovered several unique tumor response subgroups outside of response classification by Response Evaluation Criteria for Solid Tumors (RECIST), such as mixed response and oligometastasis. These subtypes have a distinctive property, lesion heterogeneity defined as dive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Dung-Tsa, Chan, Wenyaw, Thompson, Zachary J., Thapa, Ram, Beg, Amer A., Saltos, Andreas N., Chiappori, Alberto A., Gray, Jhanelle E., Haura, Eric B., Rose, Trevor A., Creelan, Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248740/ https://www.ncbi.nlm.nih.gov/pubmed/34197475 http://dx.doi.org/10.1371/journal.pone.0252041

Ejemplares similares

Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Chen, Dung-Tsa, et al.
Publicado: (2023)

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
por: Chiappori, Alberto A., et al.
Publicado: (2018)

A Bayesian pick-the-winner design in a randomized phase II clinical trial
por: Chen, Dung-Tsa, et al.
Publicado: (2017)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
por: Schabath, Matthew B., et al.
Publicado: (2015)

Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial
por: Chen, Dung-Tsa, et al.
Publicado: (2019)

Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer
por: Tanvetyanon, Tawee, et al.
Publicado: (2023)

Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
por: Chen, Lu, et al.
Publicado: (2016)

Strategies for power calculations in predictive biomarker studies in survival data
por: Chen, Dung-Tsa, et al.
Publicado: (2016)

Clinical associations of mucin 1 in human lung cancer and precancerous lesions
por: Saltos, Andreas, et al.
Publicado: (2018)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
por: Gray, Jhanelle E., et al.
Publicado: (2018)

A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses
por: Boyle, Theresa A., et al.
Publicado: (2019)

Mistic: An open-source multiplexed image t-SNE viewer
por: Prabhakaran, Sandhya, et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
por: Creelan, Ben C, et al.
Publicado: (2017)

Correction: Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
Publicado: (2021)

Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2019)

Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2021)

Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment
por: John, Sooraj, et al.
Publicado: (2017)

Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy
por: Kim, Eunjung, et al.
Publicado: (2018)

Plasma Cell‐Free DNA Genotyping: From an Emerging Concept to a Standard‐of‐Care Tool in Metastatic Non‐Small Cell Lung Cancer
por: Gray, Jhanelle, et al.
Publicado: (2021)

Genetic Heterogeneity of Benign Thyroid Lesions
por: Ferrer-Roca, O., et al.
Publicado: (1998)

Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response
por: Garg, Saurabh K., et al.
Publicado: (2020)

Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis
por: Meng, Lingbin, et al.
Publicado: (2023)

The clinical heterogeneity of late-onset MELAS
por: Atwal, H.K., et al.
Publicado: (2017)

Defining Emerging Roles for NF-κB in Antivirus Responses: Revisiting the Interferon-β Enhanceosome Paradigm
por: Balachandran, Siddharth, et al.
Publicado: (2011)

Proteogenomic landscape of squamous cell lung cancer
por: Stewart, Paul A., et al.
Publicado: (2019)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Heterogeneity of mammary lesions represent molecular differences
por: Namba, Ruria, et al.
Publicado: (2006)

A Case Control Study of the Seroprevalence of Helicobacter pylori Proteins and Their Association with Pancreatic Cancer Risk
por: Permuth, Jennifer B., et al.
Publicado: (2021)

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

Incorporating lesion-to-lesion heterogeneity into early oncology decision making
por: Kumar, Rukmini, et al.
Publicado: (2023)

The late appearance of extramedullary lesions in myelomatosis.
por: Craft, I. L.
Publicado: (1967)

BRAF Mutation Heterogeneity in Melanoma Lesions
por: SAKAIZAWA, Kaori, et al.
Publicado: (2020)

A Critical Role for the RelA Subunit of Nuclear Factor κB in Regulation of Multiple Immune-response Genes and in Fas-induced Cell Death
por: Ouaaz, Fateh, et al.
Publicado: (1999)

Unplugging the Drain: Treatment of a Rare Late Complication of Cardiac Resynchronization Therapy
por: Beg, Faheemullah, et al.
Publicado: (2019)

Targeting Trop-2 in solid tumors: future prospects
por: Zaman, Saif, et al.
Publicado: (2019)

Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer
por: Puri, Sonam, et al.
Publicado: (2020)

Review of Late-Breaking Trials From CRT 2022
por: Bhogal, Sukhdeep, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s7kl1hfcvke0dtv817mrva453n